240 related articles for article (PubMed ID: 19173823)
1. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
Tang CH; Liu XQ; Yang SF; Zhu B; Gao HJ
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effects of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on non-small lung cell cancer: an experimental with rats].
Tang YM; Yang SF; Zhu B; Cui JS
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2021-5. PubMed ID: 16313792
[TBL] [Abstract][Full Text] [Related]
3. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
[TBL] [Abstract][Full Text] [Related]
4. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
Zhang R; Ru Y; Gao Y; Li J; Mao S
Drug Des Devel Ther; 2017; 11():2631-2642. PubMed ID: 28919713
[TBL] [Abstract][Full Text] [Related]
5. Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
Wu JJ; Jiao SC
Asian Pac J Trop Med; 2013 Nov; 6(11):908-11. PubMed ID: 24083589
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
He SW; Zhang Y; Chen L; Luo WJ; Li XM; Chen Y; Huang SY; He QM; Yang XJ; Li YQ; Liu N; Zhao Y; Ma J
FASEB J; 2021 Oct; 35(10):e21885. PubMed ID: 34478585
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.
Matsumoto M; Takeda Y; Maki H; Hojo K; Wada T; Nishitani Y; Maekawa R; Yoshioka T
Jpn J Cancer Res; 2001 Jan; 92(1):51-8. PubMed ID: 11173544
[TBL] [Abstract][Full Text] [Related]
8. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Bajetta E; Stani SC; De Candis D; Zaffaroni N; Zilembo N; Cortinovis D; Aglione S; Mariani L; Formisano B; Bidoli P
Ann Oncol; 2003 Feb; 14(2):242-7. PubMed ID: 12562651
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of bcl-2 antisense oligodeoxynucleotides on growth of human lung carcinoma xenograft in nude mice].
He DM; Zhang H
Ai Zheng; 2006 Jan; 25(1):40-4. PubMed ID: 16405747
[TBL] [Abstract][Full Text] [Related]
12. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo.
Teng JP; Yang ZY; Zhu YM; Ni D; Zhu ZJ; Li XQ
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3819-3825. PubMed ID: 29949158
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of dual drugs from polymeric micelles for simultaneous targeting of both cancer cells and cancer stem cells.
Krishnamurthy S; Ng VW; Gao S; Tan MH; Hedrick JL; Yang YY
Nanomedicine (Lond); 2015; 10(18):2819-32. PubMed ID: 26377155
[TBL] [Abstract][Full Text] [Related]
17. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
19. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Vansteenkiste JF; Vandebroek JE; Nackaerts KL; Weynants P; Valcke YJ; Verresen DA; Devogelaere RC; Marien SA; Humblet YP; Dams NL;
Ann Oncol; 2001 Sep; 12(9):1221-30. PubMed ID: 11697832
[TBL] [Abstract][Full Text] [Related]
20. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
